Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene

by O'Connell RJ, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Malia J, Michael NL, Excler J, Robb ML, Kim JH
Published 2012-09-01